Medicare drug coverage
Vemlidy in Nevada: 2027 Part D coverage
71 of 100 Part D plans offered in Nevada (71%) list Vemlidy on their 2027 formulary, the plan's list of covered drugs (up 3 points from 2026). 86% of those require prior authorization, step therapy, or a quantity limit. Plan counts include both Medicare Advantage plans with drug coverage (91 MA-PD) and stand-alone drug plans (9 PDP).
License: a US government work, in the public domain (Public Domain Mark 1.0).
For pharmacies and agencies: check a whole drug list against 2027 formularies.
Upload your patient list or your book of clients and Rivvi checks each drug against the CMS 2027 formulary files, plan by plan, so you see tier changes and new limits before the next refill or open enrollment. Free to start. HIPAA BAA included.
Every 2027 plan in Nevada
Each Part D plan offered in Nevada, with Vemlidy's 2026 and 2027 tier and its 2027 limits. A tier is the cost level a plan puts a drug on; a lower tier usually costs less. Enter a ZIP to see only the plans offered in that county.
PA is prior authorization (the plan must approve it first), ST is step therapy (try another drug first), and QL is a quantity limit. D-SNP, C-SNP, and I-SNP are Special Needs Plans: for people with both Medicare and Medicaid, with certain chronic conditions, or who live in a nursing home or need that level of care. Plans are listed by plan ID.
| Plan | Plan ID | Type | 2026 tier | 2027 tier | 2027 PA / ST / QL | Change |
|---|---|---|---|---|---|---|
| Wellcare SilverSummit Healthplan Dual Liberty (HMO-POS D-SNP) | H0351-066-000 | MA-PD (HMO-POS D-SNP) | Tier 5 | Not listed | Not listed | No longer listed |
| Wellcare SilverSummit Healthplan Dual Access (HMO-POS D-SNP) | H0351-068-000 | MA-PD (HMO-POS D-SNP) | Tier 5 | Not listed | Not listed | No longer listed |
| AARP Medicare Advantage from UHC NV-0001 (HMO-POS) | H0609-028-000 | MA-PD (HMO-POS) | Tier 5 | Tier 5 | QL | No change |
| UHC Medicare Advantage NV-001P (HMO-POS) | H0609-032-000 | MA-PD (HMO-POS) | Tier 5 | Tier 5 | QL | No change |
| AARP Medicare Advantage from UHC NV-0003 (HMO-POS) | H0609-033-000 | MA-PD (HMO-POS) | Tier 5 | Tier 5 | QL | No change |
| UHC Complete Care NV-4 (HMO-POS C-SNP) | H0609-037-000 | MA-PD (HMO-POS C-SNP) | Tier 5 | Tier 5 | QL | No change |
| AARP Medicare Advantage Essentials ValueRx NV-5 (HMO-POS) | H0609-038-000 | MA-PD (HMO-POS) | Tier 5 | Tier 5 | QL | No change |
| AARP Medicare Advantage from UHC NV-0006 (HMO-POS) | H0609-040-000 | MA-PD (HMO-POS) | Tier 5 | Tier 5 | QL | No change |
| AARP Medicare Advantage Extras ValueRx NV-10 (HMO-POS) | H0609-075-000 | MA-PD (HMO-POS) | Tier 5 | Tier 5 | QL | No change |
| SCAN Classic (HMO) | H0978-001-000 | MA-PD (HMO) | Tier 5 | Tier 5 | None | No change |
| SCAN Balance (HMO C-SNP) | H0978-002-000 | MA-PD (HMO C-SNP) | Tier 5 | Tier 5 | None | No change |
| SCAN Strive (HMO C-SNP) | H0978-010-000 | MA-PD (HMO C-SNP) | Tier 5 | Tier 5 | None | No change |
| SCAN Costco Medicare Advantage (HMO) | H0978-012-000 | MA-PD (HMO) | New plan ID | Tier 5 | None | New plan ID in 2027 |
| Humana Gold Plus H1036-344 (HMO) | H1036-344-000 | MA-PD (HMO) | New plan ID | Tier 5 | QL | New plan ID in 2027 |
| UHC Dual Complete NV-Q1 (HMO-POS D-SNP) | H1360-001-000 | MA-PD (HMO-POS D-SNP) | Tier 5 | Tier 5 | QL | No change |
| UHC Dual Complete NV-S4 (HMO-POS D-SNP) | H1360-002-000 | MA-PD (HMO-POS D-SNP) | Tier 5 | Tier 5 | QL | No change |
| UHC Dual Complete NV-S5 (HMO-POS D-SNP) | H1360-003-000 | MA-PD (HMO-POS D-SNP) | Tier 5 | Tier 5 | QL | No change |
| UHC Dual Complete NV-Q2 (PPO D-SNP) | H1889-012-000 | MA-PD (PPO D-SNP) | Tier 5 | Tier 5 | QL | No change |
| UHC Dual Complete NV-S3 (PPO D-SNP) | H1889-035-000 | MA-PD (PPO D-SNP) | Tier 5 | Tier 5 | QL | No change |
| Select Health Medicare Essential (HMO) | H1994-012-000 | MA-PD (HMO) | Tier 5 | Tier 5 | PA, QL | No change |
| Select Health Medicare Value Giveback (HMO) | H1994-021-000 | MA-PD (HMO) | Tier 5 | Tier 5 | PA, QL | No change |
| Select Health Medicare Wellness (HMO) | H1994-044-000 | MA-PD (HMO) | Tier 5 | Tier 5 | PA, QL | No change |
| AARP Medicare Advantage from UHC NV-0007 (PPO) | H2001-125-000 | MA-PD (PPO) | Tier 5 | Tier 5 | QL | No change |
| AARP Medicare Advantage Giveback from UHC NV-8 (PPO) | H2001-127-000 | MA-PD (PPO) | Tier 5 | Tier 5 | QL | No change |
| UHC Dual Complete NV-S6 (PPO D-SNP) | H2001-141-000 | MA-PD (PPO D-SNP) | New plan ID | Tier 5 | QL | New plan ID in 2027 |
Data only, not plan advice. Confirm on Medicare.gov Plan Finder or 1-800-MEDICARE.
Nevada compared with the nation
90% of the 100 Part D plans offered in Nevada leave Vemlidy off the 2027 formulary or restrict it, against 89% nationally (1 point higher). Nevada is tied with 3 other states at 90% of plans restricting or leaving it off. A plan offered in several states counts in each.
2027 compared with 2026
| Measure | 2026 | 2027 | Change |
|---|---|---|---|
| Part D plans in the file | 110 | 100 | -10 |
| Plans that list it | 75 (68%) | 71 (71%) | +3 points |
| Prior authorization (of plans that list it) | 12 (16%) | 9 (13%) | -3 points |
| Step therapy (of plans that list it) | 0 (0%) | 0 (0%) | no change |
| Quantity limit (of plans that list it) | 60 (80%) | 61 (86%) | +6 points |
| Any of the three (of plans that list it) | 60 (80%) | 61 (86%) | +6 points |
| Not listed or restricted (of all plans) | 95 (86%) | 90 (90%) | +4 points |
Formulary tier
| Tier | 2026 plans | 2027 plans |
|---|---|---|
| Tier 5 | 75 (100%) | 71 (100%) |
Plan by plan, 2026 to 2027
| Plan by plan | Plans |
|---|---|
| Same plan ID in both years | 87 |
| Listed it in 2026, not in 2027 | 4 (5%) |
| Listed it in 2027, not in 2026 | 1 (1%) |
| Moved it to a higher tier | 0 (0%) |
| Moved it to a lower tier | 0 (0%) |
| Added prior authorization | 0 (0%) |
| Added step therapy | 0 (0%) |
| Added a quantity limit | 0 (0%) |
| Added at least one of the three | 0 (0%) |
| Removed at least one of the three | 0 (0%) |
| Plan IDs new in 2027 | 13 |
| 2026 plan IDs not in the 2027 file | 23 |
The CMS summary has no count of tier moves down, so "Moved it to a lower tier" is counted from the plan rows on this page: plans with the same plan ID in both years that list Vemlidy both years.
Restricted listings rose from 60 to 61, but none of the 87 plans offered in both years added prior authorization, step therapy, or a quantity limit to Vemlidy. The rise comes from plan IDs that are new in 2027: 13 new plan IDs, and 8 of them restrict it. 23 plan IDs from 2026 are not in the 2027 file.
Vemlidy in other states
- Alabama84% restrict or leave off, +5 pointsAL
- Alaska89% restrict or leave off, +22 pointsAK
- Arizona89% restrict or leave off, +10 pointsAZ
- Arkansas87% restrict or leave off, +13 pointsAR
- California71% restrict or leave off, +1 pointCA
- Colorado82% restrict or leave off, +4 pointsCO
- Connecticut98% restrict or leave off, +23 pointsCT
- Delaware86% restrict or leave off, +15 pointsDE
- District of Columbia81% restrict or leave off, +17 pointsDC
- Florida97% restrict or leave off, +6 pointsFL
- Georgia81% restrict or leave off, +13 pointsGA
- Hawaii86% restrict or leave off, +5 pointsHI
- Idaho98% restrict or leave off, +6 pointsID
- Illinois87% restrict or leave off, +6 pointsIL
- Indiana98% restrict or leave off, +7 pointsIN
- Iowa98% restrict or leave off, +15 pointsIA
- Kansas99% restrict or leave off, +11 pointsKS
- Kentucky95% restrict or leave off, +10 pointsKY
- Louisiana90% restrict or leave off, +15 pointsLA
- Maine98% restrict or leave off, +15 pointsME
- Maryland71% restrict or leave off, no changeMD
- Massachusetts68% restrict or leave off, +4 pointsMA
- Michigan98% restrict or leave off, +6 pointsMI
- Minnesota68% restrict or leave off, -2 pointsMN
- Mississippi89% restrict or leave off, +15 pointsMS
- Missouri92% restrict or leave off, +8 pointsMO
- Montana96% restrict or leave off, +7 pointsMT
- Nebraska94% restrict or leave off, +18 pointsNE
- New Hampshire96% restrict or leave off, +24 pointsNH
- New Jersey93% restrict or leave off, +12 pointsNJ
- New Mexico96% restrict or leave off, +6 pointsNM
- New York86% restrict or leave off, +15 pointsNY
- North Carolina90% restrict or leave off, +8 pointsNC
- North Dakota73% restrict or leave off, +9 pointsND
- Ohio83% restrict or leave off, +4 pointsOH
- Oklahoma94% restrict or leave off, +4 pointsOK
- Oregon92% restrict or leave off, +23 pointsOR
- Pennsylvania91% restrict or leave off, +3 pointsPA
- Rhode Island97% restrict or leave off, +7 pointsRI
- South Carolina88% restrict or leave off, +10 pointsSC
- South Dakota70% restrict or leave off, +7 pointsSD
- Tennessee90% restrict or leave off, +8 pointsTN
- Texas91% restrict or leave off, +9 pointsTX
- Utah98% restrict or leave off, +12 pointsUT
- Vermont93% restrict or leave off, +16 pointsVT
- Virginia93% restrict or leave off, +2 pointsVA
- Washington82% restrict or leave off, +20 pointsWA
- West Virginia91% restrict or leave off, +6 pointsWV
- Wisconsin93% restrict or leave off, +6 pointsWI
- Wyoming92% restrict or leave off, +13 pointsWY
About this data
A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.
A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.
Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page
Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page
Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page
Source: CMS CY2026 landscape file, as of September 25, 2025. Publisher page
Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page
Source: US Census Bureau 2020 ZCTA to county relationship file (ZIP lookup), as of December 9, 2021. Publisher page